2
The poster display was an overwhelming success
at NOPS 2005 and CAPhO invites you to begin
preparing your posters immediately for submission
(the deadline is August 31, 2006 at 16:00 PST.)
*****************************************************
Supportive-care Issues in Cancer:
An Update for the Oncology Pharmacist
CAPhO/Merck modules are now available to all
CAPhO members! In collaboration with Merck
Frosst, CAPhO has developed modules on
supportive-care issues in cancer over the last two
years. These modules were designed specifically
for the oncology pharmacist. The topics include:
• Nausea and vomiting.
• Cancer pain.
• Mucositis and Palmar-plantar
Erythrodysesthesia (PPE).
• Neutropenia.
• Bowel obstruction.
These modules are now available free of charge to
all CAPhO members via the order form which is
available on the CAPhO website in the member’s
area.
*****************************************************
Predicting the Risk of CoMorbid Events in
Cancer Patients: The Launch of a New Website
for Oncology Pharmacists
www.PredictPatientEvents.com
Submitted by George Dranitsaris, Member at Large
Dr. Mark Vincent (Medical Oncologist, London
Regional Cancer Program, Ontario) and I recently
launched a new website for estimating the percent
risk of co-morbid events in cancer patients.
Treatment induced side effects or co-morbid
events are commonly thought to be largely
unpredictable. As a result, oncology health care
providers usually take action only after the event
occurs. This means trying to "rescue" the patient
from an unpleasant and potentially dangerous
situation, and adjusting the regimen (e.g. dose
reduction) and/or institution of supportive care.
Accurately predicting and preventing significant
toxicities would substantially improve clinical
care. This might include the use of appropriate
supportive care medication, as well as
forewarning the patient and initiating a more
intensive early monitoring scheme and action
plan for early intervention. The realities of health
care systems around the world preclude this for
all patients, throughout all cycles of
chemotherapy. What may be possible, however,
is a highly focused strategy based on the
accurate prediction of patients at higher than
average risk, applied "just-in-time" to pre-empt
episodes of toxicity. This is some of the
information the website intends to provide to the
oncology clinician.
What does it provide?
The website has validated models, which provide
patient specific information on the percent risk for a
particular toxic event. The prediction models were
developed from data collected from adult cancer
patients and should not be used for patients less
than 18 years of age. Note that a user must initially
“request access” to the website (no cost).
What types of risk calculations are currently
available?
• Moderate to severe nausea and vomiting
during the first 24 hours, and for 2-5 days
following chemotherapy for a wide variety of
disease sites.
• For chemotherapy in adjuvant breast cancer, 3
risk calculators linked with blood hemoglobin
are available which provide a percent risk for
anemia either during or prior to a cycle of
chemotherapy.
• For chemotherapy in advanced non small cell
lung cancer, one anemia risk calculator is
available for assessing the risk of anemia
(defined as a blood hemoglobin ≤ 100 g/L) prior
to a cycle of palliative chemotherapy
Who should use the website?
The current website should only be used by a
qualified medical professional or an allied health
care professional, who is working under the
supervision of a treating physician. The website
should not be used by patients or family members.
Summary
This website is intended as an information tool for
the practicing oncology pharmacist. It must not
replace clinical judgment, but should be used as an